AHA writes to express our strong support for this vital program that allows eligible hospitals to maintain, improve and expand access to essential services and medications for the patients and ...
More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...
13hon MSNOpinion
Op-Ed: 340B needs transparency to fulfill Its mission
For the 5,000 people in Illinois living with sickle cell disease, access to affordable medical care and life-saving ...
Johnson & Johnson, Eli Lilly, Sanofi and Bristol Myers Squibb are suing the federal government over the future of their 340B drug rebate plans. The lawsuits reflect rising tensions among drugmakers, ...
Even as they sparred on broader healthcare policy and funding topics fueling the ongoing government shutdown, senators of the ...
The 340B Drug Pricing Program helps poor states like Kentucky. Bigstock Senate Bill 14 in the ongoing Kentucky legislative session relates to the federal 340B Drug Pricing Program. This program ...
Your recent opinion piece on the 340B drug discount program (December 18, “Drug discount program remains vital to support healthcare services”) provides a somewhat deceptive picture of the 340B ...
The 340B Drug Pricing Program was created to help a targeted group of safety net providers care for low-income and uninsured patients. First enacted as part of the Veterans Healthcare Act of 1992, ...
This past September, a sub-agency of the Department of Health and Human Services (HHS) threatened to kick a pharmaceutical company out of Medicare because the company, in line with federal law, ...
Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. "MFN reinforces the worst incentives in 340B, shifts costs ...
A federal court has sided with the U.S. Department of Health and Human Services (HHS), rejecting Johnson & Johnson’s (NYSE:JNJ) effort to reshape its participation in the 340B Drug Pricing Program.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback